Tysabri Return To Market For First-Line Use In Relapsed MS Supported By Slim Majority
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA advisory committee unanimously agrees that Biogen Idec's natalizumab should be reintroduced for at least some multiple sclerosis patients.
You may also be interested in...
Biogen Hikes Guidance On Solid Quarter
More MS patients now outside the U.S. than inside, company says.
Biogen Hikes Guidance On Solid Quarter
More MS patients now outside the U.S. than inside, company says.
FDA Re-Approves Tysabri, Recommends Second-Line Use
Biogen Idec expects to re-launch the multiple sclerosis therapy in July.